Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
deals
4
×
life sciences
national blog main
national top stories
roche
fda
clinical trials
genentech
san francisco blog main
alexion pharmaceuticals
alnylam pharmaceuticals
avapritinib
biopharma
blueprint medicines
boehringer ingelheim
cancer
cancer immunotherapy
center for medicare and medicaid services
companion diagnostic
cstone pharmaceuticals
daniel o'day
dicerna pharamceuticals
duchenne
eli lilly
europe blog main
europe top stories
european medicines agency
fisogatinib
flatiron health
foundation medicine
foundationone cdx
foundationone heme
hepatitis b
hepatitis b virus
hepatocellular carcinoma
hereditary transthyretin amyloidosis
What
roche
4
×
approval
billion
drug
fda
gene
medicine
medicines
pay
recently
team
acquire
agreed
betting
big
biopharma
blueprint
broad
cancer
candidate
caught
causing
confidence
currently
deal
dicerna
didn’t
disease
duchenne
eye
foundation
gain
genentech
hepatitis
historic
intended
marketing
momentum
morning
muscle
Language
unset
Current search:
roche
×
deals
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
